EQS-News

SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE.

EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): 9 Month figures/Preliminary Results SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE. 05.10.2022 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE.

• Non-Rx sales growth 22% in Q3 (9M 18%).
• Total sales growth 20% to EUR 285 million in Q3 (9M 14% to EUR 877M).
• Customer Net Promoter Score (NPS) again at record level well above 70.
• Active customer base grew 0.2 million in Q3 to 8.9 million (YTD increase 1 million).
• Positive adj. EBITDA margin expected for Q3.
• Adoption of eRx in Germany is progressing steadily.

Sevenum, the Netherlands, 5 October 2022. According to preliminary figures, SHOP APOTHEKE EUROPE’s non-Rx sales, currently comprising the majority of the business and accounting for around 90% of total sales, increased by 22% year over year in Q3 2022 to 252M. Total sales increased by 20% year over year to EUR 285M, with Rx sales at EUR 33 million (+4% year over year). The active customer base continued to grow – up 0.2 million in Q3 and 1 million YTD to 8.9 million at the end of September; this is 1.5 million higher compared to September last year. The measure of customer satisfaction NPS (net promoter score) was again well above 70. SHOP APOTHEKE EUROPE achieved another quarter of strong performance in the logistic and pharmacy processes at Sevenum. In Italy, a significant improvement of the NPS was achieved after the opening of SHOP APOTHEKE EUROPE’s new distribution centre in Milan this summer, shortening delivery times.

SHOP APOTHEKE EUROPE’s CEO, Stefan Feltens, comments: “We had another very successful quarter, gaining market share in each of our seven countries. This achievement was the result of our focus on customer needs and excellent execution. Simultaneously, the adoption of eRx in Germany rose; the number of e-scripts doubled from 70k in both July and August to more than 140k in September.”